Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from TempraMed Technologies Ltd. ( (TSE:VIVI) ).
TempraMed Technologies has secured a national rollout of its temperature-protection products across Super-Pharm, Israel’s largest pharmacy and health-retail chain serving millions of consumers. The partnership makes devices for safeguarding insulin, epinephrine auto-injectors and other temperature-sensitive medications widely available at point of care.
The Super-Pharm agreement marks a significant commercialization milestone, enhancing TempraMed’s visibility, patient access and product education in a core market with high prevalence of chronic conditions. Combined with its recent rollout at Maccabi Pharm, the move strengthens TempraMed’s multi-channel distribution strategy and positions Israel as a launchpad for further expansion into Europe, North America and other high-growth regions.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical device company specializing in temperature-controlled medication storage solutions for drugs such as insulin and epinephrine. Its patented, FDA-registered thermal insulation devices, including VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med, operate without batteries and support patients and healthcare providers across North America, Europe and Asia.
Average Trading Volume: 54,105
Learn more about VIVI stock on TipRanks’ Stock Analysis page.